Gimoti (metoclopramide hydrochloride) NDC 72089-307

NDC codes

FDA NDC Directory

Product NDC (as listed)72089-307Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72089-0307Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72089-307-15	72089030715	1 BOTTLE, PUMP in 1 CARTON (72089-307-15) / 9.8 mL in 1 BOTTLE, PUMPMarketed from Jun 19, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Gimoti
Generic name (nonproprietary): metoclopramide hydrochloride
Active ingredients: Metoclopramide hydrochloride — 15 mg/.07mL
Dosage form: Spray
Route: Nasal
Labeler: Evoke Pharma, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 209388
Marketing start: Jun 19, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Dopamine D2 Antagonists (Mechanism)
Identifiers: Product ID 72089-307_4b47dd3d-4a37-e136-e063-6394a90a31efSPL ID 4b47dd3d-4a37-e136-e063-6394a90a31efSPL set ID 95269b1f-779c-4ca0-9f86-e74e677f9900RxCUI 2380564, 2380570UNII W1792A2RVD
Pharmacologic class: Dopamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472089030715 followed by a unit qualifier and the quantity

Package 72089-0307-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 20, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. GIMOTI is a dopamine-2 (D 2 ) antagonist indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 ) Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. ( 1 , 8.4 ) moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased dr…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)